[{"Assets_0_Q2_USD":57177733.0,"EarningsPerShareBasic_1_Q2_USD":-0.06,"EarningsPerShareBasic_2_Q2_USD":-0.1,"EarningsPerShareDiluted_1_Q2_USD":-0.06,"EarningsPerShareDiluted_2_Q2_USD":-0.1,"NetIncomeLoss_1_Q2_USD":-1776642.0,"NetIncomeLoss_2_Q2_USD":-3142823.0,"StockholdersEquity_0_Q2_USD":33533608.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":30982497.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":30979283.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":30982497.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":30979283.0,"Ticker":"VERU","CIK":"863894","name":"FEMALE HEALTH CO","OfficialName":"Veru Inc. Common Stock","form":"10-Q","period":"20170331","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1011836411.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170510"}]